BioSpace News Archive

Carmot Therapeutics, Inc., a clinical-stage biotechnology company applying its proprietary drug discovery platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer, announced today a $160 million Series D financing.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 10th annual Regeneron Prize for Creative Innovation, a competition designed to recognize excellence and creativity in biomedical research conducted by postdoctoral fellows and graduate students.

Orthofix Announces First Clinical Use of Virtuos Lyograft – a First-of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures.

ANANDA Scientific Inc ., a research focused bio-pharmaceutical company today announced the first patient enrolled in the clinical trial evaluating Nantheia™ ATL5 , an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder.

Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that it has entered into a debt financing facility for up to $70 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.

OpGen, Inc. announced today that its subsidiary Ares Genetics GmbH (Ares Genetics) and the Belgian National Reference Centre have entered into a collaboration agreement to jointly evaluate computational tools developed by Ares Genetics for the identification and characterization of Streptococcus pneumoniae for diagnostic purposes.

Seagen Inc. and Astellas Pharma Inc. announced positive topline results from the phase 1b/2 EV-103 clinical trial Cohort K evaluating PADCEV® in combination with Merck’s anti-PD-1 therapy KEYTRUDA® as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy.

MorphoSys AG reported preliminary U.S. net product sales of Monjuvi® for the second quarter 2022 and announced an update of its financial guidance for 2022 based on the preliminary unaudited consolidated results for the first six months 2022 and following the license agreements with Human Immunology Biosciences, Inc. for felzartamab and MOR210.

Argonaut Manufacturing Services, a contract manufacturing organization serving the biopharma, life sciences, and molecular diagnostics industries, announced the launch of LyoDots,*TM the world’s smallest lyophilized reagents.

GenScript USA Inc., the world’s leading life-science research tools and services provider, announced its second annual GenScript Gene & Cell Engineering Virtual Summit, which will feature in-depth discussions and research presentations on the crucial gene-synthesis and cell-editing technologies that are transforming scientific and biomedical research.